Adlai Nortye Ltd. American Depositary Shares ANL · USD
Health Care · US listing · 🇺🇸 United States
11.15
+8.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adlai Nortye Ltd. American Depositary Shares
Its shares trade under the ticker ANL. It has been listed since 29 September 2023. In the fiscal year to 31 December 2025, it reported revenue of $5.0m and a net loss of $35.5m. At that date it held total assets of $34.4m and shareholders' equity of −$8.3m.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Sept 2023
- Employees
- 109
- Website
- adlainortye.com ↗
- Head office
- 77 ROBINSON ROAD, #20-01, SINGAPORE, 068896
- Incorporated in
- U0
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adlai Nortye Ltd. has a diverse pipeline including AN0025 for rectum cancer treatment.
- The company's AN9025 targets RAS-mutant cancers in phase 1a trials.
- Adlai Nortye's AN4035 is a CEACAM5-targeting antibody drug conjugate in development.
Weaknesses
- Adlai Nortye Ltd. has only 109 employees as of 2023.
- The company's clinical trials are in early phases with no approved products yet.
- Adlai Nortye's business includes technology transfer services as a secondary focus.
Opportunities
- Adlai Nortye's AN4005 PD-L1 inhibitor is in phase 1b trials for cancer immunity activation.
- The company's AN8025 tri-specific antibody fusion protein is in phase Ia trials for advanced tumors.
- Adlai Nortye's AN0025 is being tested in combination with radiotherapy for esophageal cancer.
Threats
- Adlai Nortye Ltd. has no approved products in the market as of 2023.
- The company's clinical trials face regulatory hurdles in the Health Care sector.
- Adlai Nortye's phase 1a trials for AN9025 may encounter safety issues.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.